Matinas Biopharma (MTNB) news

Matinas Biopharma - incurs no termination penalties or expenses from sales agreement termination - SEC filing

Matinas Biopharma Inc. has disclosed in a recent SEC filing that it incurred no termination penalties or expenses following the termination of a sales agreement [1]. The company previously entered into the agreement to facilitate the distribution of one of its pharmaceutical products. According to…

Matinas Biopharma - BTIG terminates sales agreement with Matinas Biopharma Holdings, effective immediately on July 23, 2026 - SEC filing

BTIG, a financial services firm, has announced the termination of its sales agreement with Matinas Biopharma Holdings, effective immediately as of July 23, 2026, according to a recent SEC filing[1]. The agreement, which facilitated the at-the-market offering of the company’s securities, will no…

Matinas Biopharma - proposed deal for $4.0 mln upfront, up to an additional $17.5 mln in potential milestones and future mid-single-digit royalties

Matinas Biopharma Holdings - GH Power equityholders to own 91% and Matinas equityholders 9% of GHP International post-closing

Matinas Biopharma receives notice of non-compliance with NYSE American continued listing standards and acceptance of plan to regain compliance

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has received a notice of non-compliance from the NYSE American, indicating that the company does not meet the continued listing standards outlined in Sections 1003(a)(i) through (iii) of the NYSE American Company Guide. These standards require…